+

WO2018111099A8 - Biomarqueurs et traitements de l'angiopathie amyloïde cérébrale (aac) - Google Patents

Biomarqueurs et traitements de l'angiopathie amyloïde cérébrale (aac) Download PDF

Info

Publication number
WO2018111099A8
WO2018111099A8 PCT/NL2017/050831 NL2017050831W WO2018111099A8 WO 2018111099 A8 WO2018111099 A8 WO 2018111099A8 NL 2017050831 W NL2017050831 W NL 2017050831W WO 2018111099 A8 WO2018111099 A8 WO 2018111099A8
Authority
WO
WIPO (PCT)
Prior art keywords
caa
biomarkers
treatments
amyloid angiopathy
cerebral amyloid
Prior art date
Application number
PCT/NL2017/050831
Other languages
English (en)
Other versions
WO2018111099A1 (fr
Inventor
August Benjamin Smit
Jeroen Joseph Maria Hoozemans
David Carolus HONDIUS
Johanna Maria KWAKKEL
Original Assignee
Stichting Vumc
Stichting Vu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vumc, Stichting Vu filed Critical Stichting Vumc
Publication of WO2018111099A1 publication Critical patent/WO2018111099A1/fr
Publication of WO2018111099A8 publication Critical patent/WO2018111099A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des biomarqueurs et des méthodes de diagnostic pour déterminer la présence et/ou le risque d'angiopathie amyloïde cérébrale (AAC) ainsi que des méthodes de criblage pour des traitements de l'AAC.
PCT/NL2017/050831 2016-12-12 2017-12-12 Biomarqueurs et traitements de l'angiopathie amyloïde cérébrale (aac) WO2018111099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16203467.2 2016-12-12
EP16203467 2016-12-12

Publications (2)

Publication Number Publication Date
WO2018111099A1 WO2018111099A1 (fr) 2018-06-21
WO2018111099A8 true WO2018111099A8 (fr) 2018-08-23

Family

ID=57680062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2017/050831 WO2018111099A1 (fr) 2016-12-12 2017-12-12 Biomarqueurs et traitements de l'angiopathie amyloïde cérébrale (aac)

Country Status (1)

Country Link
WO (1) WO2018111099A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230088509A1 (en) * 2020-05-20 2023-03-23 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350159A (en) 1980-02-29 1982-09-21 Gouda Kasim I Frame for stereotactic surgery
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2005047505A2 (fr) 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Techniques et produits d'expression de micro arn
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
EP2121757A2 (fr) 2007-02-21 2009-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
US8652440B2 (en) 2007-05-10 2014-02-18 The Trustees Of Columbia University In The City Of New York Methods for diagnosing diseases and evaluating treatments therefor using PET
AU2008256886B2 (en) 2007-05-23 2013-02-28 Dharmacon, Inc. Micro-RNA scaffolds and non-naturally occurring micro-RNAs
JP5420532B2 (ja) 2007-05-24 2014-02-19 アブリンクス エン．ヴェー． 骨疾患及び骨障害の治療のために、ｒａｎｋ−ｌに指向性を有するアミノ酸配列及びこれを含むポリペプチド
EP2225377B1 (fr) 2007-11-26 2014-01-08 Santaris Pharma A/S Antagonistes basés sur les lna ciblant le récepteur de l'androgène
WO2009126018A1 (fr) 2008-04-08 2009-10-15 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Système de traitement de données pet, agencement, procédé et produit de programme d'ordinateur pour déterminer une distribution d'une absorption de marqueur
CN102149728B (zh) 2008-09-10 2014-10-15 霍夫曼-拉罗奇有限公司 抑制眼部血管生成的方法
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2011008982A1 (fr) 2009-07-15 2011-01-20 Sah Dinah W Y Traitement de troubles neurologiques
JP5847717B2 (ja) 2009-08-25 2016-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳に治療剤を送達するためのカニューレ配置の最適化
CN105431161A (zh) 2013-02-21 2016-03-23 范安德尔研究所 Norrin突变体多肽、其制造方法和用途

Also Published As

Publication number Publication date
WO2018111099A1 (fr) 2018-06-21

Similar Documents

Publication Publication Date Title
EP4015531A3 (fr) Pore mutant
IL254980B (en) Prognostic and diagnostic glycan-based markers for brain damage
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
IL257461B (en) A method for quantifying organs of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii and their use as biomarkers
WO2017040526A3 (fr) Variants d'épissage associés à des mutants de sf3b1 néomorphes
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EP3546947A3 (fr) Panels de biomarqueurs pour complications de lesions cerebrales
IL269552A (en) Diagnostic methods and kits for early detection of ovarian cancer
EP3308158A4 (fr) Exosomes dérivés d'adipocytes, et compositions, kits et procédés d'utilisation de ces derniers pour détection et dépistage
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
GB2558005B (en) Adaptation of dynamic range enhancement based on noise floor of signal
IL256103B (en) Compositions and methods for treating celiac sprue disease
WO2014036040A3 (fr) Méthodes diagnostiques, pronostiques et méthodes de traitement
MX2018002467A (es) Anticuerpos y ensayos para deteccion del antigeno leucocitico (cd37).
WO2015168602A3 (fr) Procédés et compositions pour le diagnostic et le traitement de la maladie de kawasaki
EP3310353A4 (fr) Compositions et procédés pour le traitement et le diagnostic de troubles oculaires
SG10201913528PA (en) Methods of diagnosing cancer
MX388832B (es) Deteccion especifica de isoformas de clusterina.
EP3274709A4 (fr) Biomarqueurs et procédés de diagnostic et de pronostic de lésions cérabrales traumatiques légères
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
EP3292218A4 (fr) Compositions et méthodes pour la surveillance, le diagnostic, le pronostic, la détection et le traitement du cancer
EP3128326A4 (fr) Biomarqueur pour diagnostic de vieillissement ou d'amyotrophie
EP3532061A4 (fr) Traitement du prurigo nodulaire
EP3112867A4 (fr) Méthode prédictive qualitative pour diagnostic différentiel des méningites pneumococcique, méningococcique et virale, méthode et trousse de diagnostic différentiel de méningites

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17817299

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17817299

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载